International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 4 , Pages 1061-1065 , 15 March 2010

Postoperative Nomogram Predicting the 9-Year Probability of Prostate Cancer Recurrence After Permanent Prostate Brachytherapy Using Radiation Dose as a Prognostic Variable

Presented orally at the 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, October 28–November 1, 2007, Los Angles, CA.

  • Louis Potters, M.D.

      Affiliations

    • Department of Radiation Medicine, North Shore Long Island Jewish Health System, New Hyde Park, NY
    • Corresponding Author InformationReprint requests to: Louis Potters, M.D., Department of Radiation Oncology, North Shore Long Island Jewish Health System, Long Island Jewish Medical Center, 270-05 76th Ave., New Hyde Park, NY 11040. Tel: (718) 470-7190; Fax: (718) 470-0045
    • ,
  • Mack Roach III, M.D.

      Affiliations

    • Departments of Radiation Oncology and Urology, University of California at San Francisco, San Francisco, CA
    • ,
  • Brian J. Davis, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Mayo Clinic, Rochester, MN
    • ,
  • Richard G. Stock, M.D.

      Affiliations

    • Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY
    • ,
  • Jay P. Ciezki, M.D.

      Affiliations

    • Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH
    • ,
  • Michael J. Zelefsky, M.D.

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Nelson N. Stone, M.D.

      Affiliations

    • Department of Urology, Mount Sinai School of Medicine, New York, NY
    • ,
  • Paul A. Fearn, B.A.

      Affiliations

    • Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Changhong Yu, M.S.

      Affiliations

    • Glickman Urological Institute and the Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
    • ,
  • Katsuto Shinohara, M.D.

      Affiliations

    • Departments of Radiation Oncology and Urology, University of California at San Francisco, San Francisco, CA
    • ,
  • Michael W. Kattan, Ph.D.

      Affiliations

    • Glickman Urological Institute and the Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

Received 16 December 2008 ,Revised 14 February 2009 ,Accepted 9 March 2009.

References 

  1. Kattan MW, Potters L, Blasko JC, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology. 2001;58:393–399
  2. Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44:789–799
  3. Feigenberg SJ, Lee WR, Desilvio ML, et al. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys. 2005;62:956–964
  4. Lee WR, Bae K, Lawton CA, et al. A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019. Brachytherapy. 2006;5:239–243
  5. Stock RG, Ferrari AC, Stone NN. Does pelvic irradiation play a role in the management of prostate cancer?. Oncology (Huntingt). 1998;12:1467–1472discussion 1472, 1475–1476
  6. Kollmeier MA, Stock RG, Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys. 2003;57:645–653
  7. Potters L, Huang D, Calugaru E, et al. Importance of implant dosimetry for patients undergoing prostate brachytherapy. Urology. 2003;62:1073–1077
  8. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  9. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–387

 Conflict of interest: R.S. acts as a consultant for Bard. B.D. acts as a consultant for Oncura Inc. and Calypso Inc. and has a financial interest in Tomotherapy Inc. N.S. is a co-owner of Prologics, LLC. No other conflicts.

PII: S0360-3016(09)00469-6

doi: 10.1016/j.ijrobp.2009.03.031

International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 4 , Pages 1061-1065 , 15 March 2010

Article Tools

* Image Usage & Resolution